NCT03941730
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: ER-beta
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Endocrine (Hormone Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express ESR2 or Estrogen Receptor-beta
Exclusions: 
https://ClinicalTrials.gov/show/NCT03941730